The search for appropriate targets is especially important for certain malignancies such as triple-negative breast cancer (TNBC), which lack expression of the human epidermal growth factor receptor 2 (HER2/neu), estrogen or progesterone receptors, thus rendering them insensitive to available targeted therapies. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.